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Parasitic infections due to the protozoa Plasmodium are responsible for malaria, a severe 
disease that still caused about 225 million cases and 781,000 human deaths in 2009, despite 
the efforts developed during the last decade to fight this disease (Alonso et al., 2011). The 
international funding allocated to antimalarial strategies has increased regularly since 2003 
from about 0.3 billions to 1.7 billion dollars in 2009 (Collier, 2009), allowing many countries 
to undertake or strengthen effective fights against the parasite, the disease and the vectors. 
Nonetheless, more than half of the world population still lives in area where there is a risk 
of malaria transmission. The difficulty in fighting malaria is that five species of Plasmodium, 
namely P. ovale, P. malariae, P. vivax, P. falciparum and P. knowlesi (until recently considered 
as a nonhuman primate parasite) transmitted by over 30 species of Anopheles female 
mosquitoes are known to cause human malaria. The most virulent, P. falciparum, is 
responsible for severe clinical malaria and death. Furthermore, an increasing prevalence of 
resistance of vectors to insecticides, and of parasites to the standard antimalarial drugs has 
been observed for decades. 
Today, the chemotherapeutic arsenal for malaria treatment is limited to three main families 
of compounds: quinolines, antifolates and artemisinin derivatives. Recommended 
chemotherapy is based on combinations of existing drugs with artemisinin derivatives 
(artemisinin combination therapies or ACT), the only antimalarial drug having no clear 
resistance recorded but for which alarming reports of tolerance in the field indicate it could 
be just a question of time (Noedl et al., 2008). From 2000 to 2008, the use of ACT combined 
with vector control allowed to reduce considerably the number of cases of malaria in a 
dozen African countries, so that nowadays, about 50 % of the total cases of malaria in Africa 
are found in mainly five countries (Enserink, 2010). However, no new class of antimalarials 
has been introduced into clinical practice since 1996 due to the intrinsic difficulties in 
discovering and developing new antimicrobials. A recent review of the global antimalarial 
drug development (Figure 1), including drugs at various clinical stage development and 
those expected to enter in phase I studies, showed that the pipeline is rather strong but 
novelty in terms of drug targets that is required to circumvent resistance is relatively low 
(Olliaro & Wells, 2009). This situation and the complexity in developing efficient vaccines 







Fig. 1. Global antimalarial drug development pipeline (February 2009), after (Olliaro & 
Wells, 2009). Artemisinin (Art) derivatives or drugs containing the trioxane ring of 
artemisinin are illustrated in blue; aminoquinolines and structurally related compounds as 
well as aryl alcohols are in green; antibiotics are in orange; others drugs having different 
targets or mechanisms of action are in brown-red. 
2. Development of bioassays for antimalarial activity 
2.1 Malaria parasite life cycle 
P. falciparum has a complex life cycle involving the Anopheles vector, where the sexual phase 
occurs, and humans where the parasite undergoes two phases of extensive asexual 
proliferation. After the bite by an infected Anopheles, the parasites at the sporozoite stage 
enter the blood and are carried to the liver where they traverse and invade hepatocytes 
initiating what is called the hepatic or exoerythrocytic phase. During this asymptomatic 
period, that lasts 5-7 days for P. falciparum, the sporozoites develop within the hepatocytes 
and, after several rounds of mitosis, produce several thousands of new infective forms 
called the merozoites that are released into the bloodstream and invade the red blood cells. 
During this intraerythrocytic cycle, which lasts 48 h for P. falciparum and causes the malaria 
disease, the parasite undergoes a successive development into the ring stage (0-20 h) and the 
trophozoite stage (20-36 h), which then undergoes several mitoses (schizont stage, 36-48 h) 
that lead to the differentiation of 16-24 infective merozoites. Erythrocyte lysis releases the 
merozoites into the bloodstream and a new intraerythrocytic cycle can be initiated. For some 
still not well understood reasons, some merozoites differentiate into male and female 
gametocytes that are taken up by the Anopheles during the blood meal. Gametogenesis 
resumes in the digestive tract of the mosquito and sexual reproduction occurs forming a 
zygote that produces, after a meiosis and several mitosis, thousands of haploid sporozoites 
under the basal lamina, which then migrate to the salivary glands and can be transmitted to 
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humans during a bite. Different antimalarial bioassays have been developed based on the in 
vitro inhibition of parasite growth or, more recently, on the inhibition of potential parasite 
targets, allowing the screening of chemical compounds. 
2.2 Bioassays against the erythrocytic stage 
The intraerythrocytic cycle, being responsible for the symptoms of the disease, is still the 
main parasite stage against which drugs are tested. Initially, drug screenings were limited to 
the use of animal malaria models (rodent, chicken or monkey). The development of the 
continuous culture of P. falciparum on human erythrocytes (Trager & Jensen, 1976) was a 
critical advance, allowing drug evaluation on well established laboratory strains and on fresh 
isolates from patients. Typically, parasites are maintained on leucocyte-free erythrocytes at 2-
5% haematocrit, in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buffered 
Roswell Park Memorial Institute (RPMI) medium and supplemented with 5-10% human 
serum, at 37 °C, under a reduced percentage of oxygen. Hypoxanthine can be added to the 
culture medium to stimulate parasite growth and to sustain high parasitemia, and it is 
recommended for the culture of fresh isolates. Standardized protocols have been proposed e.g. 
(in Methods in Malaria Research, http://www.mr4.org/Publications/tabid/326/Default.aspx). 
Plasmodium vivax is the most widespread species and, except in equatorial Africa, is 
responsible for the most prevalent malaria infection of humans, causing 70 to 80 million 
clinical cases per year. Although P. vivax infections are rarely fatal, they remain an 
important cause of morbidity, particularly in Asia Pacific region. Compared to P. falciparum, 
P. vivax can be considered as a neglected disease. Resistance of P. vivax to the antimalarial 
drug chloroquine, the reference drug for treating P. vivax infection, has been reported since 
the 90’s. It is therefore of importance to develop tools for monitoring drug resistance and 
developing new drugs. In contrast to P. falciparum, establishment of continuous cultured 
lines of P. vivax has not yet been achieved limiting drug evaluation, particularly high 
throughput screening. P. vivax does not easily grow in culture, requiring removal of 
leucocytes and enrichment of the growth media. Parasite growth can only be performed for 
short periods, but maintaining cultures up to 4 weeks can be obtained by supplying 
reticulocytes from normal blood (Udomsangpetch et al., 2008). Drug assays developed for P. 
falciparum are transposable to fresh and cryopreserved P. vivax isolates (Kosaisavee et al., 
2006). It is generally assumed that drugs active against P. falciparum blood stages will be also 
active against P. vivax blood stages; this has been shown in clinical studies for 
dihydroartemisinin–piperaquine and for artesunate–pyronaridine (Olliaro & Wells, 2009). 
Such assumption and the technical constraints to study P. vivax explain the limited interest 
for this species. For the other human malaria parasites, P. knowlesi has been adapted to long-
term culture on monkey erythrocytes (Kocken et al., 2002) but no continuous cultivation of 
P. ovale and P. malariae has been set up.  
Standard protocols of drug and resistance evaluation on P. falciparum are recommended by 
the World Health Organisation to facilitate comparison of data. They generally involve 
evaluation by using Giemsa-stained smears and counting parasitemia or parasite stage 
distribution in treated and non-treated cultures. These assays require minimal equipment 
and can be easily applied in the field. However they are time-consuming thereby preventing 
rapid, large-scale screening of molecules. Several methods have been developed for 






2.2.1 Incorporation of radiolabelled precursors  
These assays are based on the incorporation of metabolic precursors by the parasite that 
reflects its growth. They take advantage of the fact that the red blood cell possesses a 
reduced basic metabolism. Uptake of [3H]-hypoxanthine, a precursor for nucleic acids, was 
the first described (Desjardins et al., 1979) and is still the most widely used but other 
precursors, such as [3H]-amino acids or [3H]-ethanolamine have also been described. Users 
must keep in mind that addition of hypoxanthine to the medium to sustain parasite 
development will interfere with the sensitivity of the isotopic assay using [3H]-
hypoxanthine, considered as the gold standard antimalarial drug assay. Although very 
sensitive and reproducible, applicable for high-throughput screening, these assays have 
several disadvantages. They are costly, involve radioactivity with the constraints associated 
to the manipulation of radioactive compounds and the treatment of radioactive wastes, and 
require special equipment (cell harvester, liquid-scintillation counter). They can thus be 
problematic to set up in locations with poor resources.  
2.2.2 Colorimetric assays  
Non-radioactive and low-cost alternative assays have been developed but are usually less 
standardized and often less sensitive than the [3H]-hypoxanthine uptake method. 
Colorimetric assays include the detection of Plasmodium lactate dehydrogenase (pLDH) 
activity (Makler et al., 1993), by its preferential metabolism of the substrate 3-acetylpyridine 
adenine dinucleotide which is weakly metabolized by the human LDH, or by the 
tetrazolium assay (Delhaes et al., 1999). The assays require accessible equipments 
(spectrophotometers) and good correlations were observed with the radioactive assays. 
Sensitive immunocapture assays based on monoclonal antibodies directed against pLDH 
were developed for drug screening (Druilhe et al., 2001, Makler et al., 1998) and were 
miniaturized for assays in 384-well plates (Bergmann-Leitner et al., 2008). pLDH detection 
was also the basis of rapid immunoassays for malaria diagnostic from whole blood using 
strips (OptiMal®) (Palmer et al., 1998). ELISA based on the quantification of the Plasmodium 
histidine-rich protein II (HRP2) was also developed and commercialized (Noedl et al., 2002). 
Currently, both assays are as sensitive as the isotopic assay. However, reagents are not 
widely available and their stability in field conditions may be questioned; also the genetic 
variations encountered within these parasite proteins may lead to a decrease of the assay 
sensitivity.  
2.2.3 Fluorometric and flow cytometry-based assays 
Taking advantage that erythrocytes have no or only remnant DNA/RNA, fluorescence-
based assays were developed for high-throughput drug assays using DNA-binding 
fluorophores. Fluorescence correlates parasitemia. The currently used fluorophores are 
Hoechst, DAPI, SYBRGreen I, PICO green and YOYO, the two former being less used 
because they exhibit excitation and emission properties not appropriate for current 
fluorescence plate readers and consumables, which is not the case for the latter. Protocols 
have been optimized and they propose one-step assays applicable to high-throughput 
screening and as sensitive as the isotopic and the immunocapture assays on laboratory 
strains or clinical isolates (Bacon et al., 2007, Baniecki et al., 2007, Bennett et al., 2004). The 
assays are cost-effective, requiring only a spectrofluorometer, and dyes are readily available 
www.intechopen.com
 
Advances in Antimalarial Drug Evaluation and New Targets for Antimalarials  
 
325 
worldwide. These fluorometric assays seem sufficiently sensitive to identify complex 
chemical mixtures with antiplasmodial activity such as plant extracts (Abiodun et al., 2010). 
Although several works observed similar results between the isotopic and fluorometric 
assays, users must have in mind that fluorescence intensity is highly dependent on its 
physico-chemical environment and that false positive responses due to fluorescence 
quenching by a chemical compound of the tested sample are not occasional.  
 Flow cytometry is currently used to study the biology of malaria parasites, but is still little 
used to evaluate parasite drug susceptibility, certainly because of the high cost of cytometers 
and a capacity restricted to moderate throughput assays (Grimberg, 2011). However, owing 
to the large range of fluorescent probes available having different biological or biochemical 
affinities that can be simultaneously analysed, flow cytometry allows the access to many 
more information than just parasite proliferation (DNA content). It opens a new way to 
analyse drug susceptibility by integrating the DNA content and a deeper investigation of 
biological and biochemical effects of the drug on the parasite. Quantum dot (QD) is a 
CdSe/ZnS semiconductor crystal widely used for bioimaging applications and diagnostics 
because of its high photostability, large stokes shift and narrow emission spectra. In a recent 
work, authors searched for QD chemicals that could label P. falciparum-infected erythrocytes 
and found a polyethylenglycolated cationic QD (PCQD) that specifically label erythrocytes 
infected by the late stage parasites and not the uninfected erythrocytes and the erythrocytes 
infected by the early stage parasites (Ku et al., 2011). They used PCQD to quantify the 
antimalarial effect of chloroquine in 96-well plates by flow cytometry and found the assays 
as sensitive as the pLDH assay with a comparable cost and its performance enabled high-
throughput assays. Innovative advances were also recorded for the development of assays 
using flow cytometry for evaluating drugs active on the gametocyte stage (see section 2.3). 
2.2.4 Interlaboratory variations 
Discrepancies in the activity of a same compound are often observed between laboratories. 
They can be due to the type of antimalarial assay used or to the P. falciparum strains used as 
well as their drug resistance status. However, data may also be influenced by laboratory-
specific modifications of screening conditions. One can report: 
• The use of asynchronized or synchronized cultures. P. falciparum has an asynchronous 
intraerythrocytic development in vitro. The synchronous development that is observed 
in vivo in humans can be restored by specific treatments taking into account the 
biological properties of the erythrocytes infected by the different parasite stages: e.g. 5% 
sorbitol treatment or gelatine floatation to specifically lyse or concentrate, respectively, 
the erythrocytes infected by the trophozoite and schizont stages. Assays on 
synchronized cultures of early stage parasites aim to be generalized because they reflect 
the parasite synchronisation observed in humans. Synchronous cultures allow further 
studies of the drug effects on specific stages of the parasite development.  
• The duration of the drug incubation. This can vary from the classical 48 h assays that 
are widely used, to assays of 24 h or 72 h or of a longer period, especially for evaluating 
fast or slow-acting drugs. That is particularly illustrated by drugs having a delayed-
death effect such as the antibiotics tetracyclines and clindamycin. In the presence of 
clinically relevant concentrations of these antibiotics, parasites grow normally, divide 






develop during the second erythrocytic cycle. This delayed-death effect has been 
attributed to inhibition of mitochondrion or apicoplast targets (Dahl & Rosenthal, 2008). 
Activity of such molecules would be underestimated using synchronized cultures and 
assays of less than 48 h.  
• The use of human serum or serum substitutes. Variability of quality of human serum 
batches as well as the difficulty to have access to non-immune human sera in endemic 
malaria countries can be serious problems for data reproducibility and has led to the 
evaluation of numerous serum substitutes or sera of other species to support P. 
falciparum growth in culture (Basco, 2003). Albumax® was proposed as a substitute for 
human serum and is now used routinely by many laboratories. Two types exist, 
Albumax® I and II, both are used, depending upon the authors, generally at a 
concentration of 5 g/l. Their composition is not well characterized, as well as the 
biochemical differences between both types. They are mainly composed of 
chromatographically purified fatty acid-rich bovine serum albumin and have a low IgG 
content. In addition to their high cost, batch-to-batch variability were observed in the 
past and Plasmodium strains must be adapted to culture with Albumax® (Grellier P., 
personal communication). This latter point can be problematic for evaluating drug 
resistance of fresh isolates, which have been reported to grow poorly in the presence of 
Albumax® (Basco, 2004). Furthermore, contrasted results were reported when 
comparing antimalarial drug efficacy in assays containing Albumax® or human serum. 
Some authors observed differences in the IC50 of antimalarials (Ringwald et al., 1999), 
others observed no difference (Singh et al., 2007). In our hands and in our search of 
natural products with antimalarial activity, differences of IC50 may be important 
between both conditions for some chemicals. This can be due in part to the differences 
in lipid and protein content of the two culture media and to the binding properties of 
the antimalarial that may influence the pharmacodynamic profile of the drug, as 
observed for halofantrine, a highly lipophilic drug which significantly associates to 
triglyceride rich plasma lipoproteins (Humberstone et al., 1998).  
• The culture conditions. Initial parasitemia, haematocrit, as well as atmosphere under 
which cultures are maintained (e.g., a 5% CO2 atmosphere versus a well-defined 
atmosphere such as 6% O2, 3% CO2, 91% N2) are all factors that may be the cause of 
discrepancies. For example, it has been documented that IC50 values for chloroquine 
depend highly on the oxygen pressure during the assay. A P. falciparum strain may 
display chloroquine-resistance (IC50 >100nM) at 10% O2 and behave as a sensitive strain 
at 21% O2 (Briolant et al., 2007). 
2.3 Bioassays against the gametocyte stages  
The emergence of resistance has highlighted the importance to develop drugs against 
parasite transmission (from human to Anopheles and from Anopheles to human) that has been 
recognized to be a priority in the efforts to eradicate malaria. Sexual stages (gametocytes) 
are being investigated as targets for vaccines but few drugs have been developed against 
these transmission stages. The only available compounds known to efficiently eliminate 
gametocytes are 8-aminoquinolines (primaquine and tafenoquine), but their use is restricted 
due to serious haematological toxicity. They cause haemolysis in patients with G6PD 
deficiency and, in cases of severe forms of G6PD deficiency, the risks of primaquine 
treatment might exceed the benefits (Beutler & Duparc, 2007). Difficulties to culture and to 
www.intechopen.com
 
Advances in Antimalarial Drug Evaluation and New Targets for Antimalarials  
 
327 
obtain large amounts of gametocytes have limited research in this area. Gametocytes have a 
quite long maturation period in vitro (more than 10 days), gametocytogenesis is stimulated 
by stress conditions and sexual subpopulation represents a small percentage of infected red 
blood cells. Furthermore, Plasmodium strains have a tendency to lose their capacity to 
produce gametocytes over time in culture and gametocyte-infected erythrocytes are difficult 
to separate from erythrocytes infected by asexual stages. Until recently, there had been few 
significant advances in techniques for producing gametocytes for drug screening. These 
techniques were difficult to set up and required costly equipments. New protocols have 
now improved our capability to produce gametocytes in vitro in a reproducible way, and to 
enrich gametocytes with a high degree of purity using MACS® magnetic affinity columns 
(Baker, 2007). Those improvements associated to the ability to genetically manipulate 
parasites have allowed the recent setting-up of protocols for evaluating drug effects on 
sexual conversion and gametocyte maturation with high-throughput capacities. They are 
based on : 1) the discrimination by flow cytometry of asexual and sexual forms using 
hydroethine that is taken up by the parasite and metabolized into ethidium, a nucleic acid-
binding fluorochrome (Chevalley et al., 2010); 2) the use of transgenic P. falciparum parasites 
expressing a green fluorescent protein chimera of the early sexual blood stage (protein 
Pfs16) as a marker for commitment to gametocytogenesis; this marker associated to 
hydroethine allows also to measure the direct activity of drugs against the late-stages 
gametocytes (Peatey et al., 2009). In a same way, the stage II or later stage marker 
(PF10_0164) fused to the green fluorescent protein was used associated with the nuclear dye 
Hoescht 33342 to quantify the drug effects on the asexual stages and on the sexual 
conversion and the gametocyte maturation in a same assay (Buchholz et al., 2011). In a 
general way, the application of transfection technology to malaria parasites paves the way to 
a new generation of assays targeting specific pathways or parasite stages.  
2.4 Bioassays for the hepatic stage of Plasmodium 
Drug development against the liver stage has two main advantages: 1) Such drugs could be 
used as prophylactic agents by preventing the access of the parasite to the blood and, in 
consequence, the development of the disease; 2) P. vivax and P. ovale, unlike P. falciparum, 
have latent forms (hypnozoites) in the liver responsible for relapsing infections, sometimes 
years after the primary infection. Hypnozoites are unaffected by the drugs acting on the 
erythrocytic stage. Thus, anti-hypnozoite drugs could be used as anti-relapse agents, 
limiting then recrudescences. 
The number of available drugs that act against the hepatic phase is limited. The 8-
aminoquinolines (primaquine and tafenoquine) are the main and the most efficient ones, but 
have serious haematological toxicity as already mentioned. Evaluation of drugs against the 
hepatic stage has been mainly performed using in vivo models of rodent parasites e.g., P. 
berghei and P. yoelii. However, such drug screening is time consuming and costly due to the 
need to reproduce the complete life-cycle of the parasite to obtain viable sporozoites. 
Difficulties increase greatly if screening is performed using monkey models for human 
malaria parasites. The ability to culture Plasmodium in hepatocytes has opened new 
perspectives in the research of drugs active against the hepatic stage (Mazier et al., 1985, 
Mazier et al., 2004). In vitro screenings are usually performed using sporozoites of rodent 






primary culture of human hepatocytes infected with P. falciparum sporozoites were also 
reported. Recently, assay on liver stage of P. vivax was established using purified and 
cryopreserved sporozoites opening new perspectives for development of anti-relapse drugs 
(Chattopadhyay et al., 2010). The sporozoite development within the hepatocyte into a 
schizont stage is followed either by Giemsa staining or immunofluorescence assay using 
specific antibodies or a genetically-manipulated fluorescent parasite. Potential antimalarial 
drugs acting on the hepatic stage have emerged (Carraz et al., 2006, Mahmoudi et al., 2003, 
Mahmoudi et al., 2008, Parvanova et al., 2009, Singh et al., 2010, Tasdemir et al., 2010, Yu et 
al., 2008). A high-throughput in vitro screening of drug activity on Plasmodium liver stages 
was developed based on a sophisticated infrared fluorescence scanning system, which 
allows rapid, automatic counting of infected hepatocytes (Gego et al., 2006). The recent 
development of bioluminescent parasites allows now a non-invasive real time monitoring 
and quantitative analysis of liver stage development in vitro and in vivo in rodents that offers 
new tools for drug evaluation (Mwakingwe et al., 2009, Ploemen et al., 2009) (see section 
4.3.2). Automated visual assay was also set up to follow the extracellular cell death of 
sporozoites (Hegge et al., 2010). Although promising, such assays are however greatly 
dependent upon the production of a large number of sporozoites in insects, a limiting step 
for high-throughput screening.  
2.5 Bioassays for parasite targets 
Our understanding of malaria parasite biochemistry has considerably increased over the 
past two decades and has allowed the identification of many potential targets for new 
drugs, even if half of the P. falciparum genes are still in search of a biological function 
(Florent et al., 2010). Progresses have been made possible thanks to the decrypted genomes 
of several Plasmodium species and other Apicomplexans (see www.eupathdb.org), that have 
enabled the rapid identification of putative targets that are homologous to validated targets 
in other organisms. Usually, target validation in Plasmodium requires demonstrating that a 
specific inhibitor, designed or identified as being active against this particular target, indeed 
shows antimalarial activity in vitro and/or in vivo. However, such an approach called 
“chemical-validation” has limits since it is often difficult to demonstrate that the inhibitor 
kills the parasite by indeed acting specifically on this target and not by inhibiting unrelated 
biochemical mechanisms. Thus, nowadays, “genetic-validation” of the selected target must 
also be achieved in parallel i.e., the deletion of the corresponding gene must seriously 
impair the parasite’s growth or ideally prevent its survival.  
Recent advances in genetic understanding of Plasmodium have greatly increased the ability 
to genetically validate potential drug targets (Limenitakis & Soldati-Favre, 2011). 
Methodologies able to transfect rodent Plasmodium and P. falciparum so as to modify or 
knock out genes that code for potential target proteins have been available for over a 
decade. They have been progressively improved and refined to now permit conditional 
knock out of the gene at a chosen parasite stage that may be different from the transfected 
stage (Lacroix et al., 2011), conditional elimination of the gene product by fusing a 
degradation domain and Shield ligand (Dvorin et al., 2010) or compensation of a lethal 
phenotype resulting from knock out of an essential gene by expression in trans of a wild-
type version of this gene (Slavic et al., 2010). Phenotypic analysis of the resultant mutant 
parasites then allows to study the importance of a particular target in the different phases of 
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development of the life-cycle of Plasmodium. Many putative targets, initially suspected to be 
essential to a given parasite stage turned out finally dispensable to this stage but essential to 
others (see few examples such as FabI or falcipain-1 below). Furthermore, access to 
transcriptomic and proteomic technologies offers new opportunities to study the impact of a 
drug treatment on the entire parasite metabolism either at the RNA or protein levels. This 
leads to a better understanding of the mechanism(s) of action of drugs and the biochemical 
pathways involved in killing the parasites (Sims & Hyde, 2006). Recently, the achievement 
of random mutagenesis of P. berghei and P. falciparum genome by PiggyBac transposable 
element opened the route towards systematic plasmodial gene invalidation, that will 
obviously speed up the genetic validation process of putative targets (Crabb et al., 2011). 
These recent advances have allowed development of bioassays based upon validated targets 
for drug screening, or targets still in the process of validation (for review see (Grellier et al., 
2008, Prabhu & Patravale, 2011, Sahu et al., 2008)) : haem polymerization (O'Neill et al., 
2006), pyrimidine, purine, folate (Hyde, 2007), lipid (Wengelnik et al., 2002), shikimate 
(McRobert et al., 2005), non-mevalonate (Wiesner & Jomaa, 2007) and other apicoplast 
metabolisms (Sato & Wilson, 2005), mitochondrial electron transport (Mather et al., 2007), 
redox homeostasis (Bauer et al., 2006), protein prenylation (Van Voorhis et al., 2007), 
proteases (Wegscheid-Gerlach et al., 2010), kinases (Doerig & Meijer, 2007)... Some of them 
are detailed below.  
Databases such as TDR targets (http://tdrtargets.org) gather information on putative 
targets for several pathogens including Plasmodium, providing tools for their prioritization 
in whole genomes depending on user queries (Aguero et al., 2008). The Protein Data Bank 
(www.pdb.org) is also a useful resource, providing data on proteins whose 3D-structures 
have been solved experimentally by using either X-Rays or NMR. As of September 2011, 
more than 300 entries correspond to plasmodial proteins, knowing that several structures 
involving different ligands may have been solved for a same protein.  
2.5.1 Inhibition of haeme polymerization 
Haeme polymerization (Figure 2) is a natural process that occurs in the acidic food vacuole 
of the parasite where haemoglobin, a major source of amino acids for the parasite, is 
degraded by specific proteases. Haeme, which is toxic for the parasite, is detoxified by 
polymerization into a pigment, the haemozoin. Inhibition of haemozoin formation is 
considered as an attractive target for antimalarial drugs and high-throughput assays are 
available (Biagini et al., 2003, Deharo et al., 2002, Huy et al., 2007, Ncokazi & Egan, 2005, 
Rush et al., 2009, Weissbuch & Leiserowitz, 2008). The 4-aminoquinolines such as 
chloroquine and amodiaquine act by interfering with this polymerization process. Cysteine 
and aspartic parasite proteases (falcipains and plasmepsins, respectively) involved in the 
degradation of haemoglobin are also potential targets (Wegscheid-Gerlach et al., 2010) (see 
section 2.5.2). 
2.5.2 Proteases 
Although none of the currently marketed antimalarials is targeting plasmodial proteases, 
this class of enzymes, which is involved in a wide diversity of biological pathways during 






(Wegscheid-Gerlach et al., 2010). The cystein and aspartyl endoproteases involved in the 
essential pathway of haemoglobin degradation now known as falcipain-2, 2’ and -3 and 
plasmepsin-I, -II, -III (or HAP, for histo-aspartyl protease) and –IV have first emerged as 
promising protease targets. Intensive research focused on these enzymes during the last 
decades has yielded inhibitors active down to the nM levels on the native or recombinant 
enzymes, inhibiting parasite growth in culture from the nM to µM levels and capable to cure 
Plasmodium-infected mice (McKerrow et al., 2008, Rosenthal, 2010). Gene disruption studies 
however clearly indicated that all of these enzymes besides falcipain-3 are highly 
redundant. In fact, falcipain-3 is the only for which gene disruption did not yield viable 
blood-stage parasites (Liu et al., 2006, Sijwali et al., 2006). The development of inhibitors 
targeting these enzymes but displaying improved properties in term of activity, selectivity, 
safety to the host nonetheless pertains, facilitated by their availability under recombinant 
active form, allowing both high-throughput screenings and experimental determination of 
their 3D-structures, including for the most recently described plasmepsin I (Bhaumik et al., 
2011). A strong argument for maintaining such a development against these 
haemoglobinases is linked to the proposal to use combined protease inhibitor therapy based 
on the observation that cystein and aspartyl inhibitors demonstrated synergistic antimalarial 
effects (Semenov et al., 1998).  
 
Fig. 2. Mechanisms of haemoglobin degradation and haeme detoxification in Plasmodium 
falciparum-infected red blood cell, after (Mambu & Grellier, 2008) 
In parallel, the last decade has seen the emergence as promising targets of several new 
parasite proteases, among the ~100 that are encoded in the P. falciparum genome (Wu et al., 
2003). Some are also involved in haemoglobin breakdown such as the cystein protease 
DPAP1 (Klemba et al., 2004), the metallo-endopeptidase falcilysin displaying however a 
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dual activity, both able to process peptides in the food vacuole and to mature proteins 
imported to the apicoplast (Eggleson et al., 1999, Ponpuak et al., 2007), and the metallo-
aminopeptidases PfA-M1 and PfA-M17 (McGowan et al., 2009, Skinner-Adams et al., 2009, 
Trenholme et al., 2010). Some have emerged from studies focusing on other key biological 
events such as erythrocyte egress/invasion and merozoite surface antigen maturation such 
as the subtilisin-like proteases -1 and -2 and the cystein proteases DPAP3, SERA-5 and 
SERA-6 (Blackman, 2008). Other proteases for which essential roles during the parasite 
asexual development have been demonstrated include Plasmepsin V, involved in 
maturation of proteins exported to the infected-red blood cell (Boddey et al., 2010, Russo et 
al., 2010). During these investigations, some proteases were found dispensable for the 
parasite asexual development in erythrocyte but important in other stages such as 
gametogenesis or the development of insect stages (Sologub et al., 2011). This is the case for 
the cystein proteases falcipain-1 and SERA-8. Gene deletion assays were determinant to 
indicate that falcipain-1, initially believed to be involved in haemoglobin breakdown then in 
red blood cell invasion, was in fact dispensable for the parasite blood-stage development 
but important for oocyst production (Eksi et al., 2004). Also, the P. berghei ortholog of SERA-
8 appears involved in sporozoite egress from oocysts (Aly & Matuschewski, 2005). 
2.5.3 Apicoplast-based targets 
The apicoplast is a vestigial, non-phostosynthetic, plastid-like organelle inherited from the 
prokaryotic world by secondary endosymbiosis and found in most apicomplexan parasites 
including Plasmodium that is essential to their biology. In P. falciparum, it maintains a 35-kb 
circular genome and several particular biochemical pathways that are present in bacteria 
and plants but are absent in humans, thus providing many attractive targets that are 
extensively investigated for drug development. These pathways include the type II fatty 
acid biosynthesis pathway, which involves 6 distinct enzymes in Plasmodium while in 
human the type I fatty acid biosynthesis pathway involves a multifunctional enzyme, the 1-
deoxy D xylulose 5 phosphate (DOXP) isoprenoid biosynthesis pathway that is mevalonate-
independent in the malaria parasite contrary to humans, and apicoplast replication, 
transcription and translation which involve enzymes of bacterial origins (Dahl & Rosenthal, 
2008, Goodman & McFadden, 2007, Grawert et al., 2011, Jayabalasingham et al., 2010). 
Pioneering works led to the emergence of promising antimalarials such as triclosan 
(believed to target the NADH-dependent enoyl ACP reductase or FabI enzyme), 
thiolactomycin (targeting FabH and FabB enzymes) and fosmidomycin (targeting the DOXP 
reductoisomerase) to name the main ones. Also, antibiotics such as tetracyclines and 
clindamycin, targeting prokaryotic protein synthesis, or quinolone antibiotics and 
rifampicin, targeting the prokaryotic DNA and RNA machinery, were shown to inhibit 
Plasmodium growth in culture and in vivo (Seeber & Soldati-Favre, 2010).  
These results stimulated efforts both to genetically validate these putative targets and to 
improve inhibitor discovery, by solving 3D structures and producing enzymes under 
recombinant active forms amenable to medium/high throughput screenings (Freundlich et 
al., 2007, Sato, 2011). In 2008, the genetic inactivation of FabI in P. falciparum and in P. berghei 
produced parasite blood stages that were growing normally and were still affected by 
triclosan (Yu et al., 2008). The FabI gene deletion, on the other hand, blocked the 






models of other enzymes belonging to the FasII metabolism such as FabB/F confirmed that 
the FasII pathway was dispensable through the entire parasite development to the exception 
of the hepatic-blood stage transition phase. These results raised the question of the nature of 
the parasitic target of triclosan in blood stages. Recently five laboratories reported their 
failed attempts to inhibit rodent P. berghei and P. chabaudi proliferation in mice by using 
similar doses of triclosan (Baschong et al., 2011). 
Conversely, recent works focusing on the DOXP non-mevalonate isoprenoid pathway 
confirmed it appears as a relevant target for antimalarial drug development. Key results 
include the recent failure to delete the DOXP reductoisomerase gene (Odom & Van Voorhis, 
2009). The DOXP metabolic pathway is active in all erythrocytic stages but problems with 
fosmidomycin, which has long been known to inhibit Plasmodium growth in vitro and in 
mice (Jomaa et al., 1999), emerged. Due to its short half life that may lead to parasite relapses 
and/or facilitate selection of resistant parasites, analogues with improved half-lives are 
actively looked for against this enzyme and the other enzymes of this metabolic pathway 
(Seeber & Soldati-Favre, 2010). The recent discovery that fosmidomycin is little effective 
against Theileria, Eimeria and Toxoplasma also raised the question of its bioavailability (Seeber 
& Soldati-Favre, 2010). This led to the proposal that fosmidomycin and its more active 
derivative FR900098, both active against Plasmodium erythrocytic but not hepatocytic stages, 
would enter the parasite through new permeation pathways called NPPs (Baumeister et al., 
2011). Recently also two triose-phosphate transporters present on the apicoplast membranes 
have been characterized, PfiTPT/PfAPT1 and PfoTPT/PfATP2, and are being considered as 
putative targets since they are believed to import from the cytosol into the apicoplast key 
metabolites to fuel the DOXP pathway (Lim & McFadden, 2010).  
2.5.4 Kinases 
Malarial kinases but also host cell kinases involved in host-parasite interactions are also 
currently considered as promising targets (Doerig et al., 2010). The P. falciparum theroretical 
kinome was predicted to comprise 85 to 99 enzymes, depending on the stringency of the 
computational methods used to identify them, and phylogenetic studies have revealed 
interesting differences with the human kinome that may be exploited for kinase-targeted 
drug discovery (Leroy & Doerig, 2008). For example, P. falciparum possesses kinases and 
kinase families such as calcium-dependent protein kinases (CDPK) and the apicomplexan 
specific FIKK kinase families, that are absent in humans. Important advances in this field 
have been provided by the fact that many P. falciparum kinases have been successfully 
produced as recombinant active enzymes, allowing medium/high troughput studies, many 
structures are known or can be deduced by modelling (see http://www.thesgc.com) and 
several chemical libraries, developed for other pathologies such as cancer may be screened 
on P. falciparum putative targets and parasites. For example, PfCDPK1 that has no ortholog 
in humans was produced as an active recombinant enzyme and used to screen a library of 
~20,000 molecules developed against kinases, from which a purine derivative called 
purfalcamine active to the low nM range on the enzyme was isolated (Kato et al., 2008). This 
molecule, able to prevent the P. falciparum development in culture had however a low in vivo 
activity on P. berghei, possibly due to poor pharmacokinetic parameters. Importantly, not 
only protein kinases but kinases phosphorylating other substrates such as choline kinase 
and pantothenate kinases could also be targeted (Leroy & Doerig, 2008). Genetic validation 
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of kinases may be performed by classical gene deletion in P. falciparum or rodent 
Plasmodium, but conditional expression systems have also been used as for example using 
the destabilizing domain and Shield ligand to show the involvement of PfCDPK5 in 
merozoite egress (Dvorin et al., 2010).  
2.5.5 Transporters 
Transporters are integral transmembrane proteins that enable the movement of solutes 
across biological membranes. In Plasmodium, they are currently considered as highly 
promising targets, due to their involvement, as carrier proteins, channels or pumps, in the 
movement of nutrients, metabolites and ions into and out of the parasite as well as between 
subcellular compartments within the parasite. They thus regulate essential nutrient uptake 
into the parasite, homeostasis and disposal of toxic wastes. Host cell transporters modified 
by the presence of the parasite may also be involved in these biological functions. Of note, 
malarial transmembrane proteins such as PfCRT, Pgh1, PfNHE1 and possibly PfATP6 are 
involved in drug-resistance mechanisms.  
The recent publication of the theoretical permeome of P. falciparum indicated that at least 
2.5% of the parasite genome encode transporters, channels and pumps (Martin et al., 2009). 
Experimental localizations, that have been achieved by using either specific antibodies or 
epitope-tagged or fluorescent recombinant fusion proteins transfected into parasites, 
concern few proteins of the parasite surface (PfHT1 or the hexose transporter, PfENT1 or 
PfNT1, PfMRP, PfAQP), the mitochondrial membrane (ATP/ADP transporter), or the food-
vacuole membrane (PfCRT, Pgh1, V-type H+ ATPase and ATP-driven H+ pump). Substrate 
specificities are also often ill-defined. Even if these could be predicted by orthology for 
about half of the candidates, experimental validations are still necessary to confirm or 
discover which they are. Extensive experimental work therefore needs to be done to further 
exploit such a rich source of potential targets (Staines et al., 2010). Some promising results 
nonetheless emerged in this field. First, the challenging functional expression of 
recombinant proteins, which is necessary for the biochemical testing of substrates and 
inhibitors, has been achieved successfully in Xenopus laevis oocytes for several Plasmodium 
transporters. Alternative heterologous systems have also been used such as yeast, 
Dictyostelium discoideum and mammalian cells (Martin et al., 2009). In some cases, cell-free 
transporter assay systems are used. Recently, recombinant expression of codon-optimized 
PfHT1 in yeast was performed to permit high-throughput screening of inhibitors (Blume et 
al., 2010). The P-type ATPases, PfATP4 and PfATP6, and the drug-resistance involved 
PfCRT and Pgh1 have also been expressed in such heterologous system, opening the road 
for functional studies (Martin et al., 2009). The number of known 3D-structures remains 
however extremely low, limited to PfAQP although a model has been proposed for PfHT1 
based on the structure of E. coli permease (Staines et al., 2010).  
Transfection methods have been also critical in this field, in particular to assess the role of 
PfCRT and Pgh1 in drug resistance, by transfecting P. falciparum resistant alleles into 
sensitive parasites and vice-versa, or by transfecting these alleles in various heterologous 
expression systems such as yeast (Martin et al., 2009). Gene deletion studies have been also 
undertaken, but so far for a limited number of candidates. While several genes could be 
deleted with none or limited impact on parasite asexual growth such as those encoding 






deletion of genes encoding PfHT1, PfCRT and Pgh1 could not be achieved, suggesting that 
the two latter ones play essential functions in the parasite biology beside being involved in 
drug-resistance (Sanchez et al., 2010). Such experiments performed using rodent malaria 
models further indicated that some candidates, apparently dispensable for the asexual 
development, turned out important for the development of other parasite stages in insects 
or liver (Martin et al., 2009, Staines et al., 2004). Among all these candidates, PfHT1 is the 
only malarial transporter that has been validated both chemically and genetically (Staines et 
al., 2010). Gene deletion studies and D-glucose derivatives used as inhibitors confirmed the 
essential role of the hexose transporters for the asexual parasite development and other 
parasite stages (Blume et al., 2010, Slavic et al., 2011).  
3. Renew of phenotypic screening approaches 
Advanced antimalarial drug discovery programs revealed four general strategies to 
discover new drugs (Wu et al., 2011) : 1) To start from specific, validated or not, malaria 
targets to find new hits (e.g. haem polymerization, enzymes of the pyrimidine synthesis 
pathway); 2) To synthesize new analogs from known antimalarial pharmacophores (e.g. 
synthetic endoperoxides (Trioxolanes) or hybrid molecules having two pharmacophores 
(Trioxaquines)); 3) To start from drugs developed for other diseases whose similar targets 
are present in malaria parasites (as illustrated by the piggy-back approach undertaken 
against parasite protein farnesyltransferases using anti-cancer agents targeting protein 
prenylation developed by pharmaceutical companies); 4) To screen chemicals on whole cell-
based assays to identify hits that kill parasite for further optimizations. Most of the current 
antimalarials were originated from this last phenotypic drug discovery approach. The 
revolution in molecular biology led to a switch to target-based approaches for drug 
discovery in pharmaceutical industries. However, this approach failed to deliver the 
expected results, especially for antimicrobials (Keller et al., 2011, Payne et al., 2007, Sams-
Dodd, 2005). In the recent years, the access to large chemical libraries and the improvements 
of whole cell-based high throughput screening assays led to a renaissance of the phenotypic 
approach with the forward chemical genetic strategy. Chemical genetics is the study of 
biological systems using small molecules as tools (O'Connor et al., 2011). Forward chemical 
genetic uses small molecules to modulate gene-product function leading to a phenotype of 
interest (parasite killing for example), and the target must be further identified. In contrast, 
reverse chemical genetic screens specific gene products with libraries of small molecules to 
identify ligands, which are then tested on cells for phenotypic changes. Over the last few 
years, reports demonstrated the power of chemical genetic for antimalarial drug discovery. 
The GlaxoSmithKline (GSK)’s chemical library constituted of nearly 2 million chemical 
entities was tested upon drug sensitive and multidrug resistant P. falciparum strains. More 
than 8,000 compounds, clustered into 416 molecular frameworks, showed potent 
antiplasmodial activity. Analysis of historical GSK data suggested that the main target 
classes affected by these compounds are malaria kinases, proteases and G-protein coupled 
receptors (Gamo et al., 2010). In a similar study, a library of nearly 310,000 chemicals, 
designed to cover a large diversity of bioactive compounds, was screened upon drug 
sensitive and multidrug resistant P. falciparum strains (Guiguemde et al., 2010). Amongst 
hits, 172 were cross-validated by three laboratories using distinct assays. A reverse chemical 
genetic approach was undertaken with the validated set of compounds using 66 malarial 
target assays and identified 19 new inhibitors of 4 validated targets. Preliminary 
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pharmacokinetic profiling found most of them suitable for further development. One lead 
was further evaluated in vivo on P. yoelii-infected mice and displayed significant antimalarial 
activity. In another study, the screening of a focused library of about 12,000 natural and 
synthetic chemicals led to identification of spiroindolone compounds as appropriate 
candidates for further development (Rottmann et al., 2010). Optimization studies produced 
NITD609, which is developed by Novartis.  
4. In vivo antimalarial drug evaluation 
Plasmodium species that infect humans are essentially unable to infect non-primate animal 
models. Historically, in vivo evaluation of antimalarial compounds began with the use of 
avian parasites in birds and simian parasites in monkeys. The discovery by Ignace Vincke 
and Marcel Lips in 1948 at Keyberg in the then Belgian Congo, of a rodent malaria parasite 
(Plasmodium berghei) which readily infected laboratory mice and rats, greatly facilitated in 
vivo drug screening management. Since then, several other species and subspecies of rodent 
parasites have been described and employed. With the discovery in the early 90's that the 
owl monkey (Aotus trivirgatus) is susceptible to infection with the human parasites P. 
falciparum and P. vivax, the simian models of malaria have regained interest. Infection with 
P. falciparum is now well characterized in both Aotus and Saimiri monkeys (Collins, 1992), 
and primate models, because they provide a clear prediction of drug efficacy and 
pharmacokinetics in humans, are a logical transition to clinical studies. However, there are 
obvious limitations to their use, and any primary screen dependent upon monkeys appears 
both wasteful in terms of animal conservation, drug consumption, and ethics. So, the first 
steps of in vivo drug screening typically begins with the use of mouse models of malaria 
with the rodent parasites P. berghei, P. yoelii, P. chabaudi and P. vinckei, that have been 
validated through the evaluation of several antimalarial drugs. 
4.1 Rodent models of malaria 
Individual parasite species and strains have been well characterized, including duration of 
cycle, synchronicity, drug sensitivity and course of infection in genetically defined mouse 
strains. P. berghei, P. vinckei and few strains of P. yoelii and P. chabaudi cause lethal infections 
in mice, whereas P. yoelii, P. chabaudi, and P. vinckei petterei are usually cleared after the 
initial acute parasitaemia or after a subsequent low-grade chronic parasitaemia. 
P. berghei - The strains K173, ANKA, NK65 and SP11 are the most frequently used for 
experimental work. The affinity for immature erythrocytes (reticulocytes) varies according 
to the strain. ANKA invades preferentially reticulocytes, while NK65 invades indifferently 
reticulocytes and mature erythrocytes, i.e. normocytes. Both strains are lethal, but ANKA 
kills the mouse with a low parasitaemia (it rarely exceeds 20%), whereas infection with 
NK65 induces a continuous increase in parasitaemia until the mouse dies. The erythrocytic 
cycle is asynchronous and its duration is about 21 h. Schizogony lasts 50 h in hepatocytes. 
Susceptible mice infected with P. berghei ANKA die within two weeks after infection with 
severe neurological symptoms and cerebral microvascular abnormalities. These are common 
pathologies to both murine and human infections that make of P. berghei ANKA a useful 
experimental model of cerebral malaria. Resistant mice do not show any neurological 







P. vinckei - Among four subspecies recognized (P. vinckei vinckei, P. vinckei petteri, P. vinckei 
lentum and P. vinckei brucechwatti), P. v. vinckei and P. v. petteri have been used in some 
studies for the identification of new antimalarial drugs. Both subspecies preferentially 
invade normocytes. Schizogony in erythrocytes has a duration time of 24 h and is 
synchronous. Schizogony in hepatocytes lasts for 60 h or more.  
P. yoelii – Three subspecies are recognized: P. yoelii yoelii, P. yoelii killicki and P. yoelii 
nigeriensis. P. yoelii shows a preference for reticulocytes, but it may also invade normocytes, 
depending on the virulence of the strain. Duration of the schizogonic cycle is 18 h in 
erythrocytes. Schizogony is about 45 h long in hepatocytes. The erythrocytic cycle is 
asynchronous. The parasitaemia of P. y. yoelii 17X and 265BY depends mainly on the 
production of reticulocytes by the host, whereas P. y. nigeriensis grows very rapidly by 
invading all available erythrocytes. Of note, P. yoelii is more resistant to chloroquine than are 
the other species (Beaute-Lafitte et al., 1994). Gametocyte production is constant throughout 
the infection. 
P. chabaudi – Two subspecies of P. chabaudi have been identified: P. chabaudi chabaudi and P. 
chabaudi adami. This species exhibits many similarities to P. falciparum, including analogous 
blood-stage antigens, invasion of reticulocytes and normocytes, suppression of B- and T-cell 
responses, and parasite sequestration in liver and spleen which induces parasite withdrawal 
from the peripheral circulation. The schizogonic cycle of P. chabaudi is 24 h long in 
erythrocytes and is synchronous. It runs 54-58 h in liver. In resistant mice, a rapid parasite 
multiplication during the first week p.i. is followed by parasite elimination by the fourth 
week p.i., whereas susceptible mice usually die during the second week p.i.  
4.2 Designing an experimental mouse model 
Many inbred and outbred strains of mice are available to design a mouse model. 
Considering that every species and every line or clone of a particular Plasmodium species 
exhibits particular characteristics, the resulting infection may vary greatly within the 
different laboratory strains of mice. As an example, blood-induced infections of the K173 (N) 
of P. berghei follow a fulminating course in many strains of mouse, but are slow in NMRI 
mice, and infections with P. y. yoelii 17X in Swiss mice are lethal, whereas they resolve in 
CBA/Ca mice. Scientists should use the most appropriate model for their particular research 
question and take advantage of their particular knowledge about compounds to be tested, 
especially in terms of molecular and/or biological targets. A rather rich presentation of 
experimental malaria infections in different mouse strains, comprising some models for 
cerebral malaria, can be found in (Sanni et al., 2002).  
The difference in the degree of infection, lethality and synchronicity between the rodent 
plasmodia enlarges the number of possible assays for drug evaluation. For example, 
parasites that generate high parasitaemia and synchronous infections, like P. chabaudi and 
P. vinckei, are more appropriate to study compounds exhibiting stage selectivity. Also, it is 
important to note that the drug sensitivity of a given rodent Plasmodium species may not 
reflect that of the other rodent species. This can be illustrated by P. berghei exhibiting less 
sensitivity than P. chabaudi and P. vinckei to iron chelators and lipid biosynthesis inhibitors 
(Peters & Robinson, 1999, Wengelnik et al., 2002). Drug sensitivity may also not mirror 
that of P. falciparum, as shown in the case of cysteine protease inhibitors, owing to the fact 
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that the enzyme active site is different between rodent plasmodia and P. falciparum. This 
situation has led to question the use of these models in lead optimization (Singh et al., 
2002).  
Given this, the following criteria must be considered when selecting a mouse model. On the 
host side, innate factors like peculiarities in pharmacodynamics of the drug; innate 
immunity; variation between individuals of the same species (strain, age, sex and immune 
status); environmental factors (temperature and stress, nutrition, intercurrent infections). On 
the parasite side: variation within a single Plasmodium species (variation of sensitivity 
among different clones, geographic strains, time since isolation of "wild" strain); variation 
among different Plasmodium species; mode and intensity of infection. Also, attention should 
be paid to drug-dependent factors like the mode of formulation, the route of administration 
or the drug dosage regimen. 
4.3 Current in vivo antimalarial tests using rodent models of malaria 
4.3.1 Erythrocytic stages of malaria parasites 
The most widely used initial test is the "four-day suppressive test", which commonly uses P. 
berghei or P. chabaudi. The efficacy of four daily doses of compounds is measured by 
comparison of mouse survival time and blood parasitaemia on day four p.i. in treated and 
untreated mice. Compounds identified as being active in those assays can subsequently be 
progressed through various secondary tests, such as 1) the "dose ranging, full four-day test", 
in which compounds are tested at a minimum of four different doses to determine effective 
dose values and get information on oral bioavailability and relative potency of the tested 
compounds; 2) the "onset/recrudescence" test, in which mice are administered a single dose 
on day 3 after infection and parasitaemia is monitored daily. Compounds can also be tested 
for prophylactic activity: the compound is administered prior to infection, and parasitaemia 
is followed daily.  
4.3.2 Other stages of malaria parasites 
Several tissue schizontocidal tests (the test of Gregory and Peters (1970) using sporozoites 
of P. yoelii nigeriensis, the test of Rane and Kinnamon with P. yoelii yoelii, and the Hill test 
for causal prophylactic compounds with residual action) have been reported in details 
(Peters, 1987). Tests that apply to the screening of drugs having gametocidal or 
sporontocidal action can be found at the same source. A technique such as real time PCR 
allows quantification of the parasite charge in liver and thus, the inhibitory effect of the 
molecule tested (Carraz et al., 2006). Recently, the use of a transgenic P. berghei parasite 
expressing the bioluminescent reporter protein luciferase to visualize and quantify 
parasite development in liver cells in live mice using real-time luminescence imaging was 
reported (Ploemen et al., 2009). The applicability of real time imaging to assess parasite 
drug sensitivity in the liver was demonstrated by analysing the effect of primaquine and 
tafenoquine in vivo. The methodology is relatively simple and offers the possibility to 
analyse liver development in live mice without surgery. It opens up new possibilities for 
research on Plasmodium liver infections and for evaluating the effect of drugs on the liver 






4.4 Humanized mice models of malaria 
Immunocompromized mice, developed and used in other research contexts, have been used 
for some years to elaborate new mouse models for human malaria. By grafting them with 
either human erythrocytes or human hepatocytes, these animals can support, respectively, 
the asexual blood cycle or the hepatic phase of the human parasite P. falciparum. So, drug 
efficacy and pharmacokinetics can be assessed in an in vivo setting against the true parasite 
target during its blood or hepatic stage development.  
4.4.1 The P. falciparum-human erythrocyte mouse models 
In 2001, the feasibility of evaluating in vivo responses to antimalarial drugs in humanised 
mice models was demonstrated using the P. falciparum-human erythrocyte-BXN model, in 
which Beige Xid Nude (BXN) mice, genetically deficient in T- and B-cell functions and 
chemically controlled for response of cells involved in innate defences, were grafted with 
human erythrocytes infected with P. falciparum (Moreno et al., 2001). The mice received 
human erythrocytes infected with drug (chloroquine/quinine/mefloquine) resistant or 
sensitive strains of P. falciparum, and the blood schizonticidal effects of various 
antimalarial drugs were assessed. Parasite clearance and parasite reduction rate in the 
mouse model were shown to parallel those reported in humans infected with P. 
falciparum. Since then, improvements of the P. falciparum humanized mouse model have 
been made using NSG mice with improved genetic deficiency of innate immunity. High 
reproducibility of human erythrocytes grafting and parasite survival could be achieved, 
along with the possible adjustment of parasitaemia over a range of 1-40% for several 
weeks (Arnold et al., 2011). In the near future, a model harbouring a hematopoietic stem 
cell line capable of producing erythroblasts/cytes should replace current models with the 
advantage of producing reticulocytes to also support P. vivax. To date, we are aware of 
only one work dealing with drug testing in humanised mouse model of malaria, i.e. the 
one about trioxaquine selection for drug development (Cosledan et al., 2008). The scarcity 
of reports exemplifies the serious limitations to the use of such malaria models in drug 
discovery: 1) in most of the models, parasitaemia remains stable only in a minor subset of 
mice whereas it is rapidly cleared in the majority of the animals, 2) the use of toxic 
reagents to minimize the mouse innate defence is susceptible to affect the efficacy of 
antimalarials or effector cells, 3) management of those experimental models is 
cumbersome and requires specific facilities. 
4.4.2 The P. falciparum-human hepatocyte mouse models 
There have been many attempts to develop laboratory models supporting the survival of 
human hepatocytes, given that in vivo only human cells or those of higher primates are 
receptive to P. falciparum. Invasion by and development of P. falciparum in human 
hepatocyte-transplanted animals was demonstrated in 2006, by combining 1) the use of mice 
with two genetic deficiencies (uPA-SCID mice) affecting hepatocytes and T and B 
lymphocytes, and 2) the pharmacological control of their non-adaptive defences, which 
improved the results of xenotransplantation into mice (Morosan et al., 2006). In these mice, 
P. falciparum sporozoites delivered intravenously infected the transplanted human 
hepatocytes and developed into liver schizonts up to a size that was comparable to that 
found in humans and chimpanzees. Alternative approaches to elaborate human hepatocyte-
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engrafted mouse models have been reported recently. One used the Fah–/–Rag2–/–Il2rg–/– 
mice, the liver of which was very efficiently repopulated (up to approximately 95% of the 
murine liver) by human hepatocytes under selection pressure by the drug NTBC (2-(2-nitro-
4-fluoromethylbenzoyl)-1,3-cyclohexanedione) (Bissig et al., 2010). The suitability of this 
model for antiviral drug testing after successful infection of the chimeric liver by hepatitis B 
and C viruses was demonstrated, legitimating to believe in future successful infection by 
human Plasmodium species. Also, very recently, researchers at the MIT developed artificial 
humanised mouse livers engineered by growing human hepatocytes and human liver 
endothelial cells with mouse fibroblasts in a three-dimensional polymeric scaffold, and 
implanted them into mice (Chen et al., 2011). The ectopic livers responded to drugs in a way 
very similar to the way a human liver does. 
4.5 Comments 
Obviously those recent experimental models are not yet elaborated enough to meet the 
requirements for examining the large number of compounds involved in initial drug 
development. However, they pave the way for more efficient testing of drugs designed for 
humans. Ultimately, the combination of the immunocompromised mouse model for the 
liver stage and the model for the blood stage should open access to the complete cycle of the 
P. falciparum development in a small laboratory host, thereby providing an opportunity that 
should have numerous applications not only in the field of drug testing, pharmacokinetics 
and toxicology, but also in vaccine development and to investigate some of the biological 
and physiological aspects of human malaria. 
Whatever will be the future of these new models, it seems however that exploration of drug 
potency using the "classical" rodent models might already be improved by considering some 
points of interest that we would like to list hereafter. 1) Because rodent malaria species can 
differ significantly in sensitivity to certain classes of compounds, as illustrated above with 
iron chelators and lipid biosynthesis inhibitors, it may be recommended to test new 
compounds on different models. 2) Also, the aspect of synergy between drugs should be 
considered and examination of therapies in conjunction with antimalarials typically given to 
treat patients with malaria should be favoured. 3) Notions of chronobiology may help in the 
selection of an experimental model and in the interpretation of chemotherapy experiments. 
Indeed, specific characteristics such as the duration of the schizogonic cycle, the time of 
schizogony or the synchronicity/asynchronicity of the chosen Plasmodium species and strain 
may influence its responsiveness to a drug depending on the time of administration and 
half-life of the drug (Beaute-Lafitte et al., 1994). This can be easily understood in the case of 
active compounds that preferentially affect a particular period of the parasite life cycle. 
Drug administration could be planed such that the peak level of the drug in the blood will 
be reached at the time the sensitive stage of the parasite is present in the circulation. It is 
assumed that such timing should increase the efficacy of drug treatment and minimize the 
dose to be injected. 4) Finally, it is remarkable that most of the drug testing performed in 
laboratories and promoted as potential therapy is carried out before the onset of malaria 
symptoms, whereas drug administration to treat human malaria is initiated after the onset 
of symptoms. Primary screening would gain advantage if new compounds were tested also 







This last decade, the international mobilization dedicated to antimalarial strategies has 
regularly increased, allowing many countries to undertake or strengthen effective fight 
against the parasite, the disease and the vectors, and leading to a slowing-down, even a 
decline in some place, of malaria all over the world, thanks to the usage of impregnated bed 
nets and the setting-up of artemisinin combination therapies. However, the resistance of the 
insect vectors to insecticides and of the parasites to the current antimalarial drugs, especially 
to artemisinin derivatives, is still increasing and problematic since no new class of 
antimalarials has been introduced since 1996. The current global antimalarial drug 
development shows that the pipeline of antimalarials is rather strong in term of initiatives 
but also rather weak in term of novelty of mechanism of action that is necessary to 
circumvent resistance. This situation results in an urgent need for new drugs with original 
mechanisms of action. This last decade has also seen a considerable increase in our 
understanding of malaria parasite biochemistry that has allowed the identification of many 
potential targets for new drugs such as apicoplast metabolisms, proteases, kinases, 
transporters… That has been made possible thanks to the decrypted genomes of several 
Plasmodium species, to our ability to genetically validate potential drug targets and to the 
access to the transcriptomic and proteomic technologies that offer new opportunities to 
study the impact of drugs on the entire parasite metabolism.  
These advances associated to the setting-up of high-throughput screening platforms on 
whole-cells or on specific parasite targets, and to the access to large chemical libraries with 
broad chemical diversity have seen the recent emergence of new potential antimalarial 
drugs with original molecular frameworks and mechanisms of action, that are auspicious 
for the future of antimalarial drug development. We are however facing important 
challenges in the next decade to propose efficient global antimalarial drug development. 
This will require :  
1. Ability to propose efficient heterologous expression and folding systems to produce 
recombinant active proteins for targets, in order to set up high-throughput screening 
assays or to obtain 3D-dimensional structure elucidations using X-ray crystallography 
for drug design.  
2. Development of researches on P. vivax, which can be considered as a neglected disease 
when compared to the efforts developed for P. falciparum whereas P. vivax infection is 
more widespread and remains an important cause of morbidity.  
3. Strengthening researches on drugs acting on the liver parasite stages, including 
hypnozoites, and the parasite transmission stages, in order to propose an antimalarial 
drug strategy not only acting on the disease by itself due to the intraerythrocytic 
parasite development, but also acting on the disease transmission and the disease 
relapse in the case of P. vivax.  
Finally, it must be kept in mind that for any promising molecule that will be selected, 
administration to patients will be the acid test. That is why development of small, easy to 
manage in vivo models as close to humans as possible remains a really challenging part 
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